Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
457 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04620954 | Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin(ORION-02) | unknown | Phase 1 / Phase 2 | 31 | National Cancer Centre, SingaporeOTHER | 1 | Dec 1, 2021 | clinicaltrials |
| NCT00375219 | Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation | completed | Phase 2 | 103 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY |
| 10 |
| Nov 15, 2021 |
| clinicaltrials |
| NCT04699071 | Trial of Lenvatinib Plus PembrolizumAb in Recurrent Gynecological Clear Cell Adenocarcinomas (LARA) | unknown | Phase 2 | 10 | National University Hospital, SingaporeOTHER | 1 | Oct 21, 2021 | clinicaltrials |
| NCT02038933 | Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139) | completed | Phase 2 | 121 | Bristol-Myers SquibbINDUSTRY | 12 | Oct 14, 2021 | clinicaltrials |
| NCT00880009 | Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast Cancer | terminated | Phase 2 | 16 | PfizerINDUSTRY | 7 | Sep 27, 2021 | clinicaltrials |
| NCT03093870 | Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer(TreeTopp) | completed | Phase 2 / Phase 3 | 151 | ASLAN PharmaceuticalsOTHER | 11 | Aug 3, 2021 | clinicaltrials |
| NCT03952325 | Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC(CONTESSA TRIO) | terminated | Phase 2 | 294 | Odonate Therapeutics, Inc.INDUSTRY | 3 | Jul 30, 2021 | clinicaltrials |
| NCT00742027 | Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma | completed | Phase 2 | 129 | Novartis PharmaceuticalsINDUSTRY | 13 | Jul 28, 2021 | clinicaltrials |
| NCT03451084 | A Dose Optimisation Study of ASLAN003 in Acute Myeloid Leukemia | completed | Phase 2 | 24 | ASLAN PharmaceuticalsOTHER | 3 | Jul 6, 2021 | clinicaltrials |
| NCT00109707 | A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies | completed | Phase 1 / Phase 2 | 507 | Novartis PharmaceuticalsINDUSTRY | 22 | Jun 29, 2021 | clinicaltrials |
| NCT02804776 | PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery(PROGRESS) | completed | Phase 2 | 15 | National Cancer Centre, SingaporeOTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT01610336 | A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment | completed | Phase 2 | 161 | Novartis PharmaceuticalsINDUSTRY | 14 | Apr 8, 2021 | clinicaltrials |
| NCT01915602 | Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 14 | BayerINDUSTRY | 21 | Apr 8, 2021 | clinicaltrials |
| NCT02162719 | A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors(LOTUS) | completed | Phase 2 | 124 | Genentech, Inc.INDUSTRY | 8 | Mar 10, 2021 | clinicaltrials |
| NCT04554680 | Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy | unknown | Phase 2 | 5 | National University Hospital, SingaporeOTHER | 1 | Mar 5, 2021 | clinicaltrials |
| NCT01207440 | Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)(PACE) | completed | Phase 2 | 449 | Ariad PharmaceuticalsINDUSTRY | 11 | Feb 2, 2021 | clinicaltrials |
| NCT02927925 | A Study to Assess the Clinical Efficacy and Safety of Daratumumab in Participants With Relapsed or Refractory Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type | completed | Phase 2 | 32 | Janssen Research & Development, LLCINDUSTRY | 5 | Jan 14, 2021 | clinicaltrials |
| NCT02992340 | Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment naïve Advanced or Metastatic BTC | terminated | Phase 1 / Phase 2 | 204 | ASLAN PharmaceuticalsOTHER | 3 | Jan 14, 2021 | clinicaltrials |
| NCT01602315 | A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | terminated | Phase 1 / Phase 2 | 179 | Novartis PharmaceuticalsINDUSTRY | 9 | Dec 29, 2020 | clinicaltrials |
| NCT00411528 | Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer | completed | Phase 2 | 185 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 17, 2020 | clinicaltrials |
| NCT00670592 | Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies | completed | Phase 1 / Phase 2 | 111 | Novartis PharmaceuticalsINDUSTRY | 11 | Dec 17, 2020 | clinicaltrials |
| NCT00708292 | A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma. | completed | Phase 1 / Phase 2 | 29 | Novartis PharmaceuticalsINDUSTRY | 5 | Dec 17, 2020 | clinicaltrials |
| NCT01084330 | Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer | completed | Phase 2 | 68 | Novartis PharmaceuticalsINDUSTRY | 14 | Dec 10, 2020 | clinicaltrials |
| NCT01271920 | Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab | completed | Phase 1 / Phase 2 | 45 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 8, 2020 | clinicaltrials |
| NCT04627961 | A Trial of LONSURF in Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 33 | National University Hospital, SingaporeOTHER | 1 | Nov 13, 2020 | clinicaltrials |
| NCT00983801 | Study of Ixabepilone in Asian Subjects With Unresectable or Metastatic Gastric Cancer | completed | Phase 2 | 58 | R-PharmINDUSTRY | 5 | Oct 28, 2020 | clinicaltrials |
| NCT01816230 | Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM | completed | Phase 1 / Phase 2 | 36 | Gamida Cell ltdINDUSTRY | 5 | Oct 22, 2020 | clinicaltrials |
| NCT02318368 | A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label(FOCAL) | terminated | Phase 2 | 10 | AVEO Pharmaceuticals, Inc.INDUSTRY | 7 | Oct 22, 2020 | clinicaltrials |
| NCT02217163 | Carfilzomib, Cyclophosphamide, Dexamethasone in Transplant Eligible Newly Diagnosed High-risk Multiple Myeloma | completed | Phase 2 | 30 | Singapore General HospitalOTHER | 1 | Oct 20, 2020 | clinicaltrials |
| NCT04533321 | A Biomarker-implemented Clinical Study Evaluating Mutations in MET and TP53 in a Population of Treatment-refractory Squamous Cell Carcinoma | unknown | Phase 2 | 20 | National University Hospital, SingaporeOTHER | 1 | Aug 31, 2020 | clinicaltrials |
| NCT04104113 | Health-related Quality of Life-intervention in Survivors of Breast and Other Cancers Experiencing Cancer-related Fatigue Using Traditional Chinese Medicine: The HERBAL Trial(HERBAL) | unknown | Phase 2 | 80 | National University of SingaporeOTHER | 1 | Jun 16, 2020 | clinicaltrials |
| NCT02343406 | Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas(INTELLANCE-2) | completed | Phase 2 | 266 | AbbVieINDUSTRY | 21 | May 22, 2020 | clinicaltrials |
| NCT00367718 | Trial of VELCADE in Patients With Metastatic or Locally Recurrent Nasopharyngeal Carcinoma | withdrawn | Phase 2 | 0 | Johns Hopkins UniversityOTHER | 2 | May 18, 2020 | clinicaltrials |
| NCT02336451 | A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges(Ascend-7) | completed | Phase 2 | 156 | Novartis PharmaceuticalsINDUSTRY | 17 | Apr 21, 2020 | clinicaltrials |
| NCT01466660 | LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung | completed | Phase 2 | 319 | Boehringer IngelheimINDUSTRY | 14 | Apr 7, 2020 | clinicaltrials |
| NCT01507168 | A Study of GC33 (RO5137382) in Patients With Advanced or Metastatic Hepatocellular Carcinoma | completed | Phase 2 | 185 | Hoffmann-La RocheINDUSTRY | 13 | Apr 3, 2020 | clinicaltrials |
| NCT03124433 | Neoadjuvant Apalutamide (ARN509) and Radical Prostatectomy in Treatment of Intermediate to High Risk Prostate Cancer | completed | Phase 2 | 30 | Singapore General HospitalOTHER | 1 | Mar 19, 2020 | clinicaltrials |
| NCT00625846 | Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer | completed | Phase 2 | 152 | National Cancer Institute (NCI)NIH | 5 | Feb 26, 2020 | clinicaltrials |
| NCT02031458 | A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer(BIRCH) | completed | Phase 2 | 667 | Hoffmann-La RocheINDUSTRY | 19 | Jan 6, 2020 | clinicaltrials |
| NCT02339558 | Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer | completed | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 3 | Sep 13, 2019 | clinicaltrials |
| NCT01877083 | Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung | completed | Phase 2 | 25 | Eisai Inc.INDUSTRY | 5 | Aug 13, 2019 | clinicaltrials |
| NCT00414271 | Neo-adjuvant Chemotherapy in Locally Advanced Gastric Cancer | completed | Phase 2 | 18 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 25, 2019 | clinicaltrials |
| NCT01309633 | Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC) | completed | Phase 2 | 80 | National University Hospital, SingaporeOTHER | 1 | Jul 22, 2019 | clinicaltrials |
| NCT01543776 | Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer | completed | Phase 2 | 72 | University of ChicagoOTHER | 2 | Jul 5, 2019 | clinicaltrials |
| NCT01289041 | BKM120 as Second-line Therapy for Advanced Endometrial Cancer | completed | Phase 2 | 70 | Novartis PharmaceuticalsINDUSTRY | 13 | May 30, 2019 | clinicaltrials |
| NCT03552458 | Effects of Probiotics in Preventing Oral Mucositis | unknown | Phase 2 | 50 | National University Hospital, SingaporeOTHER | 1 | Apr 30, 2019 | clinicaltrials |
| NCT00282100 | Adjuvant Therapy of Gefitinib (Iressa, ZD1839) in Patients With Resectable Hepatocellular Carcinoma | unknown | Phase 2 | 40 | Tan Tock Seng HospitalOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT02409576 | Pilot Study of Expanded , Activated Haploidentical Natural Killer Cell Infusions for Sarcomas(NKEXPSARC) | unknown | Phase 1 / Phase 2 | 20 | National University Hospital, SingaporeOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT00735917 | Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 3 | Apr 2, 2019 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials